NEWS & MEDIA

Image Alt Text

NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS WHICH ALLOWS TO PROCEED WITH THE CLINICAL DEVELOPMENT INTO PHASE III

THE BIOLOGICAL OBJECTIVE AND THREE OUT OF FOUR CLINICAL OBJECTIVES WERE MET:

  • Highly statistically significant efficacy in reduction of interferon signature
  • Lack of statistically significant clinical efficacy measured by BICLA[1]score
  • Statistical trend on clinical efficacy measured by SRI-4[2]  with reduction of steroid less than or equal to 5mg/day
  • Statistically significant clinical efficacy on the LLDAS[3] score
  • Favorable safety profile of IFNalpha Kinoid treatment

 

Read More